In Russia, a 39-year-old patient found that the inguinal lymph node was noticeably enlarged in July 2023. The patient was subsequently diagnosed with follicular lymphoma carrying the high-risk gene variant del17p13/TP53 (a complex non-Hodgkin's lymphoma) after a series of medical examinations. Despite receiving 3 periods of standard chemotherapy and molecular targeted therapy, only partial response was achieved on the disease assessment, showing poor therapeutic response. This result urged the patient to seek more advanced options and eventually came to GHG medial center for treatment.

In GHG medial center, the patient underwent a complete examination and conditioning chemotherapy, followed by two mCD19-CAR-T cell therapies in October 2023, reaching a total dose of 5.58×10^6/kg. During the treatment, the patient received comprehensive symptomatic and supportive treatment, including laminar flow bed protection and prevention for viral and fungal infections to ensure safe passage through the myelosuppression period. It is worth mentioning that the patient did not develop cytokine release syndrome(CRS) or immune effector cell-associated neurotoxicity syndrome(ICANS) reactions during the treatment, and dynamic monitoring showed good CAR-T cell expansion. The patient was discharged uneventfully on November 14, 2023.